Repare therapeutics inc RPTX.US Overview Analysis
RPTX AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has been awarded the top rating for its value, but its dividend score is below 2. If the company starts distributing dividends, it may yield even better investment results.
RPTX Current Performance
7.81%
Repare therapeutics inc
-2.56%
Avg of Sector
-1.54%
S&P500
Top 10 High Relevance to RPTX
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
EDIT | Editas medicine inc | 3 | 1 | 2 | 1 | 1 | |
MURA | Mural oncology plc | - | 4 | 2 | 1 | 1 | |
ARVN | Arvinas inc | 3 | 1 | 2 | 3 | 1 | |
TEM | Tempus ai inc | - | 2 | 2 | 2 | 1 | |
TXMD | Therapeuticsmd incorporated | 3 | 2 | 2 | 1 | 1 |
- EDIT Editas medicine incValue 3Trend 1Swing Trading 2Whale Interest 1Dividend 1See more
RPTX Profile
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.